I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Bladder urothelial cancer (BUC) is among the most common malignancies worldwide. A total of 74% cases of bladder cancers are superficial at the time of diagnosis.\[[@ref1]\] Approximately 50% of patients with superficial bladder cancers experience a recurrence within 6--12 months, and approximately 5--30% show progression to muscle-invasive cancer that has a 60--70% 5-year mortality.\[[@ref2]\] Valuable predictors of recurrence are extremely limited for patients with bladder cancer, with the exception of tumor stage and grade, as well as the presence of carcinoma *in situ*. Therefore, the discovery of new and more effective biomarkers for bladder cancer is critical, not only for accurate evaluation of tumor recurrence and progression but also as a target for anticancer therapy.

The human gene Tat-interacting protein 30 (*TIP30*), also known as *CC3* or *HITATIP2*, was first identified as a suppressor of variant small-cell lung carcinoma (vSCLC).\[[@ref3]\] *TIP30* expression is downregulated in various tumors with poor prognosis such as vSCLC,\[[@ref3]\] glioblastoma,\[[@ref4][@ref5][@ref6][@ref7]\] breast carcinoma,\[[@ref8][@ref9]\] gastric carcinoma,\[[@ref10]\] hepatocellular cancer,\[[@ref11][@ref12][@ref13][@ref14]\] laryngeal carcinoma,\[[@ref15]\] esophageal carcinoma,\[[@ref16]\] colorectal cancer,\[[@ref17]\] lung cancer,\[[@ref18]\] and pancreatic cancer.\[[@ref19]\] *TIP30* shows a positive effect in inhibiting cancer development and progression; however, its role in BUC has not previously been investigated.

In the present study, we performed immunohistochemistry (IHC) on tissue microarrays (TMAs) that contained BUC and normal bladder mucosa to investigate TIP30 expression, and analyzed the relationship between TIP30 and clinicopathological features. We aimed to investigate the expression and clinical significance of TIP30 in BUC. In addition, the correlation between TIP30 expression and prognosis was also analyzed. TIP30 might be a prognostic marker for BUC and a valuable target for the treatment on patients with BUC.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

The study was conducted in accordance with the *Declaration of Helsinki* and approved by the local ethics committee of the institute (No: 2016010). Written informed consent was obtained from all patients or their guardians for children, before study enrollment.

Patients and follow-up {#sec2-2}
----------------------

Tissues from patients with BUC were retrospectively identified from the Department of Pathology of the First Affiliated Hospital of Wenzhou Medical University between 2004 and 2007. None of these patients received preoperative chemoradiotherapy within 3 months of surgery. All patients who were treated with transurethral resection (TUR) of the bladder tumor or with partial cystectomy and who were histopathologically confirmed to have BUC were monitored through cystoscopy and urine cytology every 3 months during the first 2 years. From the 3^rd^ year, patients without recurring malignancy were evaluated once per year. All cases were classified both according to the World Health Organization (2004) and World Health Organization (1973) for grade. Normal bladder mucosal specimens were obtained via TUR or partial cystectomy and used as controls. Recurrence was defined as the diagnosis of a new pTa or pT1 tumor, while progression was defined in terms of the development of muscle invasive lesions (pT2 or higher) or metastasis, or both.

Tissue specimens and tissue microarray building {#sec2-3}
-----------------------------------------------

A total of 79 samples of BUC, along with 15 specimens of the normal bladder mucosa, were included in this study. TMAs were prepared as described previously by Kononen *et al*.\[[@ref20]\] A fresh hematoxylin and eosin (H and E)-stained section was prepared from each donor tissue block and used as a guide to define the morphologically representative regions of the tumor or normal mucosa for subsequent sampling. The chosen regions of each donor block were punched with a 0.6-mm diameter tissue cylinder and transferred to the donor paraffin-embedded block (recipient block). A 4-mm section was stained with H and E to assess the presence of the target tissue through light microscopy.

Immunohistochemistry {#sec2-4}
--------------------

We immunohistochemically processed 4-μm sections from the formalin-fixed, paraffin-embedded TMA. We deparaffinized the TMA sections in xylene, and re-hydrated them in descending dilutions of ethanol. Epitope retrieval was induced through heat treatment at 100°C for 15 min. We used the LabVision™ Autostainer 360 (Thermo Fisher Scientific, Inc., Fremont, CA, USA) to perform immunostaining. We then incubated the sections with 0.3% hydrogen peroxidase to block endogenous peroxidase activity (30 min at room temperature).

The slides were incubated overnight in the Autostainer with an antibody against TIP30 according to the manufacturer\'s recommendation (1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Nuclei were counterstained with hematoxylin. The positive control sample was normal bladder mucosa, and the negative control was the same normal tissue without the antibody.

Evaluation of immunostaining {#sec2-5}
----------------------------

Image-Pro Plus 6.0 (IPP6.0, MediaCybernetics, Inc., Bethesda, MD, USA) was used to analyze the immunoexpression levels of TIP30. The measurement parameter was the integrated optical density (*A*). All images were verified by two pathologists who were blinded to the results of the previous assessments. In cases of disagreement, a consensus was reached by discussion.

Statistical analysis {#sec2-6}
--------------------

Data analyses were performed using SPSS 13.0 (SPSS Inc., Chicago, IL, USA). The differences between groups were evaluated using the *t*-test or matched-pairs test. All statistical tests were two-tailed. The curves for disease-free survival (DFS) and overall survival (OS) were drawn using the Kaplan-Meier method, and differences in the survival rates were analyzed using the log-rank test. Prognostic factors were evaluated through univariate and multivariate analyses (Cox proportional hazards regression model). Continuous variables with normal distribution were presented as means ± standard deviation (SD), while skewed distributed variables were expressed as median (range). A value of *P* \< 0.05 was considered statistically significant. DFS was measured from the surgical resection day until either recurrence or death without recurrence, and it was censored only for patients who were alive without evidence of recurrence at the last follow-up. OS was counted from the day of surgical resection until death from any cause and was censored only for patients known to be alive at last follow-up.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Patient characteristics {#sec2-7}
-----------------------

The clinicopathologic characteristics of the 79 patients are summarized in [Table 1](#T1){ref-type="table"}. Patients with tumors consisted of nine women and 70 men, and 15 of these also had normal mucosa (seven women and eight men). The mean age at presentation was 68.8 ± 11.1 years (range, 37--91 years). Tumor specimens were obtained through TUR (*n* = 75; 94.9%) or partial cystectomy (*n* = 4; 5.1%), and 15 samples of normal mucosal tissue were obtained using the same method during surgeries. The tumor group included 39 primary tumors and 40 recurrences. The series contained 9 pTa, 51 pT1, and 19 pT2--3 tumors, among which eight, 41, and 30 were classified as papillary urothelial neoplasm of low malignant potential carcinoma (PUNLMP), low-grade papillary urothelial carcinoma (LG), and high-grade papillary urothelial carcinoma (HG), respectively, and 25, 28, and 26 were classified as Grade I, II, and III, respectively. The median follow-up period for all patients was 60.7 ± 29.2 months (range, 6--159 months).

###### 

Correlations between TIP30 expression and clinicopathological characteristics of patients with BUC

  Characteristics         *n*   Mean density      *t*/*F*    *P*
  ----------------------- ----- ----------------- ---------- --------
  Sex                                                        
   Male                   70    0.3857 ± 0.1549   0.65\*     0.52
   Female                 9     0.3496 ± 0.1770              
  Age                                                        
   ≤65 years              28    0.3692 ± 0.1329   −0.55\*    0.58
   \>65 years             51    0.3884 ± 0.1693              
  Tumor grade (WHO2004)                                      
   PUNLMP                 8     0.4911 ± 0.1300   17.48^†^   \<0.01
   LG                     41    0.4408 ± 0.1237              
   HG                     30    0.2715 ± 0.1416              
  Tumor grade (WHO1973)                                      
   Grade I                25    0.4598 ± 0.1170   10.68^†^   \<0.01
   Grade II               28    0.4037 ± 0.1522              
   Grade III              26    0.2828 ± 0.1472              
  Tumor size                                                 
   ≥3 cm                  39    0.3616 ± 0.1751   1.12\*     0.27
   \<3 cm                 40    0.4011 ± 0.1359              
  Treatment method                                           
   TUR                    75    0.3966 ± 0.1455   4.02\*     \<0.01
   Partial cystectomy     4     0.1010 ± 0.0782              
  Tumor multiplicity                                         
   Single                 32    0.3783 ± 0.1692   −0.15\*    0.88
   Multiple               47    0.3839 ± 0.1494              
  Clinical tumor stage                                       
   Superficial            60    0.4450 ± 0.1156   10.89\*    \<0.01
   Muscle invasive        19    0.1814 ± 0.0831              
  Recurrence                                                 
   No                     39    0.4096 ± 0.1801   1.58\*     0.12
   Yes                    40    0.3543 ± 0.1263              
  Progression                                                
   No                     51    0.4107 ± 0.1733   2.63\*     0.01
   Yes                    28    0.3286 ± 0.1040              

\**t* value; ^†^*F* value. TIP30: Tat-interacting protein 30; BUC: Bladder urothelial cancer; PUNLMP: Papillary urothelial neoplasm of low malignant potential; LG: Low-grade papillary urothelial carcinoma; HG: High-grade papillary urothelial carcinoma; TUR: Transurethral resection.

Tat-interacting protein 30 expression in tissue microarray sections {#sec2-8}
-------------------------------------------------------------------

IHC staining for TIP30 protein was identified in the cytoplasm of both normal mucosa and BUC specimens \[[Figure 1](#F1){ref-type="fig"}\]. Representative images of TIP30 IHC staining are shown in [Figure 1](#F1){ref-type="fig"}. TIP30 expression in patients with BUC was significantly decreased compared with that in normal mucosa (0.549 ± 0.065 vs. 0.663 ± 0.066, *t* = −6.91, *P* \< 0.01). These data suggest that decreased TIP30 expression might be involved in the carcinogenesis of BUC. TIP30 protein expression differed significantly among different differentiated groups classified according to the World Health Organization (2004) (*F* = 17.48, *P* \< 0.01) or World Health Organization (1973) (*F* = 10.68, *P* \< 0.01). TIP30 expression did not differ significantly between PUNLMP and LG BUC (*P* = 0.97), however, it was significantly reduced in HG BUC compared with PUNLMP (*P* \< 0.05) and LG BUC (*P* \< 0.05). Meanwhile, TIP30 expression did not differ significantly between Grade I and Grade II BUC (*P* = 0.45), however, it was significantly reduced in Grade III BUC, compared with Grade I (*P* \< 0.05) and Grade II (*P* \< 0.05). TIP30 expression in the muscle-invasive stage was significantly lower than that in the nonmuscle-invasive stage (*t* = 10.89, *P* \< 0.01). Patients with low TIP30 expression showed a higher incidence of tumor progression compared with those with high TIP30 expression (*t* = 2.63, *P* \< 0.05). This result indicates that reduced TIP30 expression might be correlated with the progression and prognosis of BUC. TIP30 expression in patients treated with TUR was significantly higher than that in those treated with partial cystectomy (*t* = 4.02, *P* \< 0.01). Furthermore, no significant differences in TIP30 expression were observed with regard to age, sex, tumor number, or tumor size of patients with BUC (*P* \> 0.05).

![TIP30 expression in BUC and normal urothelium on IHC. (a) Weak TIP30 staining in the cytoplasm of high-grade BUC (×200). (b) Strong TIP30 staining in the cytoplasm of BUC with normal bladder mucosa (×200). TIP30: Tat-interacting protein 30; BUC: Bladder urothelial cancer; IHC: Immunohistochemistry.](CMJ-131-188-g001){#F1}

Correlation between Tat-interacting protein 30 expression and bladder urothelial cancer prognosis {#sec2-9}
-------------------------------------------------------------------------------------------------

In this study, the median *A* of patients with BUC was 0.372. All patients were assigned to either a high TIP30 expression group (*A* ≥0.372.) or a low TIP30 expression group (*A*\<0.372).

Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"} show the Kaplan-Meier survival curves for patients with BUC tumors with high or low TIP30 expression. The OS of patients with low TIP30 expression was significantly lower than that of patients with high TIP30 protein expression (*χ*^2^ = 17.29, *P* \< 0.001; [Figure 2](#F2){ref-type="fig"}). However, the DFS of the two groups did not significantly differ (*χ*^2^ = 0.15; *P* = 0.70; [Figure 3](#F3){ref-type="fig"}).

![Patients with high TIP30 expression showed significantly lower overall survival rates than those with low TIP30 expression (*χ*^2^ = 17.29, *P* \< 0.001). TIP30: Tat-interacting protein 30.](CMJ-131-188-g002){#F2}

![Disease-free survival was not significantly different between the group with high TIP30 expression and group with low TIP30 expression (*χ*^2^ = 0.15; *P* = 0.70). TIP30: Tat-interacting protein 30.](CMJ-131-188-g003){#F3}

The results of univariate and multivariate analyses for the DFS of patients with BUC are shown in [Table 2](#T2){ref-type="table"}. Univariate analysis showed that TIP30 protein expression (*χ*^2^ = 13.32, *P* \< 0.01), tumor grade (*χ*^2^ = 15.48, *P* \< 0.01), and tumor stage (*χ*^2^ = 8.60, *P* \< 0.01) were significant prognostic factors of OS. However, age, sex, size, and number of tumors had no prognostic significance (*P* = 0.21, 0.22, 0.97, and 0.12, respectively). Meanwhile, multivariate analyses showed that TIP30 protein expression (*χ*^2^ = 5.55, *P* = 0.02) and tumor grade (*χ*^2^ = 15.18, *P* \< 0.01) were significant prognostic factors of OS.

###### 

Univariate and multivariate analyses of related factors for predicting the overall survival of patients with bladder cancer in a Cox proportional hazards model

  Variables               Univariate analysis   Multivariate analysis                                  
  ----------------------- --------------------- ----------------------- -------- ------- ------------- --------
  Sex                                                                                                  
   Male/female            1.73                  0.72--4.17              0.22     1.79    0.65--4.84    0.33
  Age                                                                                                  
   \>65 years/≤65 years   1.60                  0.77--3.34              0.21     1.34    0.63--2.88    0.45
  Tumor grade                                                                                          
   G II + III/G I         8.58                  2.94--25.03             \<0.01   11.56   3.37--39.58   \<0.01
  Clinical tumor stage                                                                                 
   T2 + T3/Ta + T1        3.36                  1.50--7.56              \<0.01   1.23    0.42--3.60    0.70
  Size                                                                                                 
   \<3 cm/≥3 cm           0.99                  0.51--1.90              0.97     0.59    0.25--1.39    0.22
  Multiplicity                                                                                         
   Multiple/single        0.59                  0.30--1.14              0.12     0.63    0.31--1.29    0.21
  Smoking                                                                                              
   Yes/no                 1.09                  0.55--2.14              0.81     0.95    0.33--2.74    0.93
  Drinking                                                                                             
   Yes/no                 0.88                  0.43--1.83              0.74     0.77    0.27--2.25    0.64
  TIP30 expression                                                                                     
   Strong/weak            0.25                  0.12--0.53              \<0.01   0.29    0.10--0.81    0.02

*HR*: Hazard ratio; *CI*: Confidence interval; TIP30: Tat-interacting protein 30.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

As a putative tumor suppressor gene, *TIP30* is decreased in several cancer cell types and is involved in the regulation of tumor cell growth and metastasis.\[[@ref9]\] As a transcription cofactor, *TIP30* may suppress the expression of genes that are involved in proliferation, apoptosis, angiogenesis, and metastasis,\[[@ref21][@ref22][@ref23]\] suggesting that *TIP30* may act as a cancer suppressor. For example, overexpression of *TIP30* has been shown to suppress tumor invasion through the extracellular matrix.\[[@ref9]\] The restoration of *TIP30* expression resulted in reduced expression of cyclin D1, *Bcl*-2, and *Bcl-xl*, but also led to overexpression of *p* 27, *Bax*, *p*53, and caspase 3 and 9; resulted in cell cycle G0/G1 arrest; induced apoptosis in human gastric cancer-derived cells; and led to significantly attenuated tumor growth and abrogation of metastasis in mouse models.\[[@ref10]\] Moreover, previous studies showed similar results, demonstrating that *TIP30* overexpression in various cell lines resulted in increased expression of several proapoptotic genes and angiogenic inhibitors and reduced expression of angiogenic stimulators.\[[@ref5][@ref6][@ref24]\]

Downregulation of *TIP30* has been found to lead to the expression of osteopontin, matrix metalloproteinase-2, and vascular endothelial growth factor, suggesting that downregulation of this protein promotes metastatic progression of lung cancer.\[[@ref18]\] Chen and Shtivelman\[[@ref25]\] found that inhibition of *TIP30* expression allowed tumor cells to evade apoptosis through glucose deprivation, and studies on animal models showed that *TIP30*-/- mice spontaneously developed tumors faster than wild-type mice.\[[@ref26][@ref27]\] Meanwhile, *TIP30* knockdown led to prolonged epidermal growth factor receptor (EGFR) signaling in early endosomes, along with delayed EGFR degradation and increased EGFR nuclear location, leading to increased expression of *pAKT* and *pERK1/2* in human lung adenocarcinoma cells.\[[@ref27]\] *TIP30* deletion enhanced proliferation of primary mammary epithelial cells and resulted in rapid immortalization of mammary epithelial cells *in vitro* relative to wild-type cells.\[[@ref28]\]

The role of *TIP30* in tumorigenesis is also evidenced by the reduced expression of TIP30 in human colorectal cancer.\[[@ref17]\] The decreased TIP30 expression is associated with poor prognosis in patients with hepatocellular carcinoma.\[[@ref12]\] Human hepatocellular carcinoma with methylated TIP30 has shown a tendency toward significantly high recurrence and mortality rates and low DFS.\[[@ref25]\] *TIP30* can also induce apoptosis and mitochondrial dysfunction, probably through stabilization of *p53* mRNA, and this mechanism is blocked by inhibition of p53 expression.\[[@ref6]\]

Comparison of the *TIP30* cDNA sequences in the National Center for Biotechnology Information databases revealed the presence of *TIP30* missense mutation in approximately 24% of various types of cancer cells.\[[@ref26]\]

Therefore, *TIP30* might play important roles in both the suppression of tumorigenesis and tumor invasion. However, the role of *TIP30* in BUC is largely unknown. In the present study, we evaluated TIP30 expression in bladder cancer and normal bladder mucosal tissues using TMA and IHC. The results showed significantly lower average expression levels of TIP30 in bladder cancer tissues than those in normal bladder mucosal tissues, suggesting that TIP30 expression might play an important role in bladder tumorigenesis. We also found that TIP30 expression was reduced significantly in invasive bladder cancer compared with superficial bladder cancer (*P* \< 0.05). TIP30 expression did not differ significantly between PUNLMP and LG BUC (*P* = 0.97), however, it was significantly reduced in HG BUC compared with PUNLMP (*P* \< 0.05) and LG BUC (*P* \< 0.05). Meanwhile, TIP30 expression did not differ significantly between Grade I and Grade II BUC (*P* = 0.45), however, it was significantly reduced in Grade III BUC, compared with Grade I (*P* \< 0.05) and Grade II (*P* \< 0.05). TIP30 expression in patients treated with TUR was significantly higher than that in those treated with partial cystectomy (*P* \< 0.01). However, this finding might be meaningless because of the small sample size, and because tumors with a broad base were always identified by cystoscopy before surgery in patients treated with partial cystectomy. Patients with low TIP30 expression showed a higher incidence of disease progression than those with high TIP30 expression (*P* \< 0.05). Kaplan-Meier survival analysis showed a strong positive relationship between TIP30 expression and OS (*P* \< 0.05).

Some limitations should be clarified. The normal bladder mucosa specimens in this study were insufficient in number to allow analysis and differentiation among BUC specimens. The mechanisms by which *TIP30* inhibits the development of BUC remain elusive and further studies should be designed to evaluate these issues.

In summary, loss of *TIP30* expression might be associated with BUC tumorigenesis and is an independent predictor for OS in patients with BUC. We believe that evaluation of *TIP30* might assist in the development of new criteria for determining the prognosis of patients with BUC. Moreover, *TIP30* might be a new and valuable target for the development of therapeutic strategies for patients with BUC.
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